Categories
Tag: MOPC
Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8+ T cells
Introduction Interleukin (IL)-2 was the first Food and Drug Administration approved immunotherapy for use in patients with metastatic melanoma and renal cell carcinoma.1 2 However, the use of recombinant IL-2 (Proleukin/aldesleukin) has been problematic due to low response rates, off-target effects, and severe dose-dependent toxicities. Due to its potent T-cell…
A human metallothionein pseudogene containing AG/CT repetitive elements
Crabtree GR, Kant JA (1982) Organization of the rat γ-fibrinogen gene: alternative mRNA splice patterns produce the γα and γβ (γ′) chains of fibrinogen. Cell 31:159–166 Article PubMed Google Scholar Durnam DM, Palmiter RD (1981) Transcriptional regulation of the mouse metallothionein-I gene by heavy metals. Proc Natl Acad Sci USA…